Mar 05, 2020 9:30am EST PROCESSA PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD
Feb 13, 2020 9:30am EST PROCESSA PHARMACEUTICALS APPOINTS GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS
Dec 20, 2019 4:10pm EST PROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK
Dec 04, 2019 9:30am EST PROCESSA PHARMACEUTICALS PROVIDES AN UPDATE ON POSITIVE RESULTS FROM PCS-499 PHASE 2 TRIAL
Sep 03, 2019 9:30am EDT PROCESSA PHARMACEUTICALS ANNOUNCES THE LICENSING OF AN ANTI-FIBROTIC, ANTI-INFLAMMATORY DRUG FOR THE TREATMENT OF MULTIPLE UNMET MEDICAL NEED CONDITIONS
Aug 26, 2019 9:30am EDT PROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
Jul 15, 2019 9:30am EDT PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
May 20, 2019 9:30am EDT PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE JEFFRIES 2019 GLOBAL HEALTHCARE CONFERENCE ON FRIDAY, JUNE 7TH, 2019
Mar 11, 2019 5:30am EDT PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE COWEN CONFERENCE ON WEDNESDAY - MARCH 13, 2019
